EP1064022A4 - HLA BINDING PEPTIDES AND THEIR APPLICATIONS - Google Patents
HLA BINDING PEPTIDES AND THEIR APPLICATIONSInfo
- Publication number
- EP1064022A4 EP1064022A4 EP98910404A EP98910404A EP1064022A4 EP 1064022 A4 EP1064022 A4 EP 1064022A4 EP 98910404 A EP98910404 A EP 98910404A EP 98910404 A EP98910404 A EP 98910404A EP 1064022 A4 EP1064022 A4 EP 1064022A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hla
- binding peptides
- peptides
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/005039 WO1999045954A1 (en) | 1998-03-13 | 1998-03-13 | Hla-binding peptides and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1064022A1 EP1064022A1 (en) | 2001-01-03 |
EP1064022A4 true EP1064022A4 (en) | 2004-09-29 |
Family
ID=22266589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98910404A Withdrawn EP1064022A4 (en) | 1998-03-13 | 1998-03-13 | HLA BINDING PEPTIDES AND THEIR APPLICATIONS |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1064022A4 (ja) |
JP (1) | JP2002507397A (ja) |
AU (1) | AU6465598A (ja) |
CA (1) | CA2323632A1 (ja) |
WO (1) | WO1999045954A1 (ja) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
WO2000020445A2 (en) * | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
GB9826143D0 (en) | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
KR20010080661A (ko) * | 1998-12-01 | 2001-08-22 | 교고 이또 | 신규의 종양 항원 단백질 art-1 및 이의 종양 항원펩티드 |
IT1309584B1 (it) * | 1999-02-26 | 2002-01-24 | San Raffaele Centro Fond | Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso. |
WO2001032193A1 (en) * | 1999-10-29 | 2001-05-10 | Argonex Pharmaceuticals | Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma |
CA2386341A1 (en) * | 1999-11-18 | 2001-05-25 | Epimmune Inc. | Heteroclitic analogs and related methods |
CA2393738A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
JP2003516131A (ja) * | 1999-12-10 | 2003-05-13 | エピミューン, インコーポレイテッド | ペプチドおよび核酸組成物を使用する、p53に対する細胞性免疫応答の誘導 |
EP1235841A4 (en) * | 1999-12-10 | 2006-04-12 | Epimmune Inc | TRIGGERING MAGE2 / 3 CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
EP1244465A4 (en) * | 1999-12-21 | 2005-01-12 | Epimmune Inc | INDUCTION OF CELLULAR IMMUNE RESPONSE TO PROSTATE CANCER BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
FR2806727A1 (fr) * | 2000-03-23 | 2001-09-28 | Pf Medicament | Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable |
AU2001253029A1 (en) * | 2000-03-30 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer |
CN1107681C (zh) * | 2000-08-11 | 2003-05-07 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
JP2004522412A (ja) * | 2000-08-14 | 2004-07-29 | コリクサ コーポレイション | Her−2/neu−関連悪性腫瘍の治療および診断のための組成物および方法 |
EP1313505A4 (en) * | 2000-09-01 | 2005-10-12 | Epimmune Inc | HLA BINDING PEPTIDES AND THEIR USES (18.03.02) |
EP1195381A1 (de) * | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
WO2002042325A2 (en) | 2000-10-31 | 2002-05-30 | Zycos Inc. | Cyp1b1 nucleic acids and methods of use |
CA2439990A1 (en) * | 2001-03-01 | 2002-09-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office | Immunogenic hiv peptides for use as reagents and vaccines |
US7252824B2 (en) * | 2001-03-07 | 2007-08-07 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
EP1752160A3 (en) * | 2001-04-06 | 2007-05-30 | Mannkind Corporation | Epitope sequences |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
AU2002305138A1 (en) | 2001-04-09 | 2002-10-21 | Mayo Foundation For Medical Education And Research | Methods and materials for cancer treatment |
US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
WO2002094994A2 (en) | 2001-05-18 | 2002-11-28 | Mayo Foundation For Medical Education And Research | Chimeric antigen-specific t cell-activating polypeptides |
EP1531860A4 (en) * | 2001-06-05 | 2005-11-02 | Us Gov Health & Human Serv | PEPTIDES FOR THE DIAGNOSIS OF CHLAMYDOPHILA PNEUMONIAE AND THE VACCINE AGAINST CHLAMYDOPHILA PNEUMONIAE |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
CA2357906A1 (en) | 2001-09-28 | 2003-03-28 | Institut Pasteur | Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections |
DE60238864D1 (de) * | 2001-11-07 | 2011-02-17 | Mankind Corp | Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption |
EP1462456A4 (en) * | 2001-12-10 | 2005-09-21 | Greenpeptide Co Ltd | TUMOR ANTIGENS |
WO2003087126A2 (en) * | 2002-04-05 | 2003-10-23 | Epimmune Inc. | Heteroclitic analogs and related methods |
EP2336189A1 (en) | 2003-01-28 | 2011-06-22 | Proscan RX Pharma | Prostate cancer diagnosis and treatment |
JPWO2005007694A1 (ja) * | 2003-07-16 | 2007-09-20 | 株式会社グリーンペプタイド | HER2/neuペプチドおよびその治療上の用途 |
JP5097400B2 (ja) * | 2003-09-03 | 2012-12-12 | デンドリセラピューティクス、インク. | 複合ワクチン |
US7488793B2 (en) * | 2003-09-22 | 2009-02-10 | Ludwig Institute For Cancer Research | Isolated peptide which binds to HLA-Cw*07 and uses thereof |
EP2062590A1 (en) * | 2003-09-22 | 2009-05-27 | Green Peptide Co., Ltd. | Peptide derived from Hepatitis C virus |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
WO2005103679A2 (en) | 2004-04-21 | 2005-11-03 | Algonomics Nv | Method for affinity scoring of peptide/protein complexes |
EP1757687A4 (en) * | 2004-04-30 | 2008-01-16 | Nec Corp | HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR |
WO2006035681A1 (ja) * | 2004-09-27 | 2006-04-06 | National University Corporation Tokyo Medical And Dental University | HLA-A11拘束性Tax抗腫瘍エピトープ |
JP5116150B2 (ja) * | 2005-09-07 | 2013-01-09 | 日本電気株式会社 | Hla結合性ペプチド、それをコードするdna断片および組み換えベクター |
WO2007120834A2 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
WO2008010010A1 (en) * | 2006-07-12 | 2008-01-24 | Vaxon Biotech | Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
EP2586460A1 (en) | 2007-10-16 | 2013-05-01 | Peptimmune, Inc. | Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes |
US8728492B2 (en) | 2008-01-18 | 2014-05-20 | Aeras Global Tb Vaccine Foundation | Malaria vaccine compositions and constituents which elicit cell mediated immunity |
WO2010086294A2 (en) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
CA2775720A1 (en) * | 2009-09-30 | 2011-04-07 | Saint Louis University | Peptides for inducing heterosubtypic influenza t cell responses |
JP5930967B2 (ja) * | 2010-09-08 | 2016-06-08 | 学校法人 埼玉医科大学 | C型肝炎ウイルスリポソームワクチン |
JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
CN102286075A (zh) * | 2011-08-01 | 2011-12-21 | 中国人民解放军第三军医大学 | 乙肝病毒表面抗原的免疫显性hla-a*1101限制性ctl表位及其应用 |
EP3444262A3 (en) * | 2011-09-09 | 2019-04-10 | Agency For Science, Technology And Research | P53 activating peptides |
AU2013210783B2 (en) * | 2012-01-20 | 2017-12-07 | Cellvax Therapeutics Inc. | Autologous cancer cell vaccine |
JP5999703B2 (ja) * | 2013-01-09 | 2016-09-28 | 国立大学法人 東京医科歯科大学 | HLA−DR1拘束性Tax特異的CD4+T細胞エピトープ |
WO2016131856A1 (en) * | 2015-02-18 | 2016-08-25 | F. Hoffmann-La Roche Ag | Immunoconjugates for specific induction of t cell cytotoxicity against a target cell |
CN105037559B (zh) * | 2015-08-17 | 2018-09-25 | 北京康爱瑞浩生物科技股份有限公司 | 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法 |
TWI796642B (zh) | 2015-08-28 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 |
GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
CN111148528A (zh) | 2016-12-28 | 2020-05-12 | 英福瓦克思公司 | 流感疫苗 |
US11517591B2 (en) | 2017-09-01 | 2022-12-06 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to BCMA and TACI antigens |
EP3545967A1 (en) * | 2018-03-28 | 2019-10-02 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer immunization platform |
US20230087348A1 (en) * | 2019-01-11 | 2023-03-23 | Agency For Science, Technology And Research | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
BR112021017404A2 (pt) * | 2019-03-04 | 2022-02-01 | Univ Health Network | Receptores de células t e métodos de uso dos mesmos |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003205A1 (en) * | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
WO1997033602A1 (en) * | 1996-03-11 | 1997-09-18 | Cytel Corporation | Peptides with increased binding affinity for hla molecules |
WO1997034617A1 (en) * | 1996-03-21 | 1997-09-25 | Cytel Corporation | Hla binding peptides and their uses |
WO1997034621A1 (en) * | 1996-03-21 | 1997-09-25 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
WO1998032456A1 (en) * | 1997-01-23 | 1998-07-30 | Epimmune, Inc. | Identification of broadly reactive dr restricted epitopes |
-
1998
- 1998-03-13 EP EP98910404A patent/EP1064022A4/en not_active Withdrawn
- 1998-03-13 WO PCT/US1998/005039 patent/WO1999045954A1/en active Application Filing
- 1998-03-13 JP JP2000535367A patent/JP2002507397A/ja active Pending
- 1998-03-13 CA CA002323632A patent/CA2323632A1/en not_active Abandoned
- 1998-03-13 AU AU64655/98A patent/AU6465598A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003205A1 (en) * | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
WO1997033602A1 (en) * | 1996-03-11 | 1997-09-18 | Cytel Corporation | Peptides with increased binding affinity for hla molecules |
WO1997034617A1 (en) * | 1996-03-21 | 1997-09-25 | Cytel Corporation | Hla binding peptides and their uses |
WO1997034621A1 (en) * | 1996-03-21 | 1997-09-25 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
WO1998032456A1 (en) * | 1997-01-23 | 1998-07-30 | Epimmune, Inc. | Identification of broadly reactive dr restricted epitopes |
Non-Patent Citations (4)
Title |
---|
ALTUVIA YAEL ET AL: "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets", HUMAN IMMUNOLOGY, vol. 58, no. 1, November 1997 (1997-11-01), pages 1 - 11, XP002279422, ISSN: 0198-8859 * |
GREY H M ET AL: "CLASS I MHC-PEPTIDE INTERACTIONS: STRUCTURAL REQUIREMENTS AND FUNCTIONAL IMPLICATIONS", CANCER SURVEYS, OXFORD, GB, vol. 22, 1995, pages 37 - 49, XP008024840 * |
PARTIDOS C D ET AL: "Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides", IMMUNOLOGY, vol. 87, no. 2, 1996, pages 179 - 185, XP002279421, ISSN: 0019-2805 * |
See also references of WO9945954A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU6465598A (en) | 1999-09-27 |
CA2323632A1 (en) | 1999-09-16 |
EP1064022A1 (en) | 2001-01-03 |
JP2002507397A (ja) | 2002-03-12 |
WO1999045954A1 (en) | 1999-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064022A4 (en) | HLA BINDING PEPTIDES AND THEIR APPLICATIONS | |
HUP0102535A3 (en) | Cd19xcd3 specific polypeptides and uses thereof | |
PL344341A1 (en) | Peptides | |
PL346346A1 (en) | Cyclic prosaposin-derived peptides and uses thereof | |
IL128869A0 (en) | Pyrozolopyrimidines and pyrazolotriazines | |
EP1021185A4 (en) | DIHYDROPYRIMIDINE AND ITS USES. | |
EP0894807A4 (en) | GPIb lipid complex and its applications | |
IL131368A0 (en) | Antipathogenic synthetic peptides and compositions comprising them | |
GB9806806D0 (en) | Peptides and uses thereof | |
EP1056465A4 (en) | ANTIMICROBIAL PEPTIDES AND DERIVATIVE METAPEPTIDES | |
ZA97283B (en) | Isolated tyrosinase derived peptides and uses thereof | |
EP0750679A4 (en) | ISOLATED PEPTIDES DERIVED FROM TYROSINASE AND USES THEREOF | |
IL131707A0 (en) | Acetylcholinesterase-derived peptides and uses thereof | |
GB9825854D0 (en) | Peptide | |
GB9718110D0 (en) | Peptides | |
HK1046925A1 (zh) | Mage-a12抗原肽及其用途 | |
GB9918155D0 (en) | Proteins and peptides | |
GB9714276D0 (en) | Peptides and related compounds | |
GB9812675D0 (en) | Peptides | |
GB9700154D0 (en) | Peptides | |
HK1039636A1 (zh) | 髓磷脂碱性蛋白肽及其應用 | |
IL145711A0 (en) | Thrombospondin-2 and uses thereof | |
EP0998578A4 (en) | SEL-10 AND USES OF SEL-10 | |
EP0996457A4 (en) | PEPTIDES RELEASERS OF F.S.H. | |
GB9917165D0 (en) | Polypeptides polynuclcotides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000929 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EPIMMUNE INC. |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 14/82 B Ipc: 7C 07K 14/02 B Ipc: 7C 07K 7/00 B Ipc: 7A 61K 39/00 B Ipc: 7A 61K 39/29 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040813 |
|
17Q | First examination report despatched |
Effective date: 20070820 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080401 |